NO983002D0 - Vitronectin receptor antagonists - Google Patents
Vitronectin receptor antagonistsInfo
- Publication number
- NO983002D0 NO983002D0 NO983002A NO983002A NO983002D0 NO 983002 D0 NO983002 D0 NO 983002D0 NO 983002 A NO983002 A NO 983002A NO 983002 A NO983002 A NO 983002A NO 983002 D0 NO983002 D0 NO 983002D0
- Authority
- NO
- Norway
- Prior art keywords
- receptor antagonists
- vitronectin receptor
- vitronectin
- antagonists
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US953295P | 1995-12-29 | 1995-12-29 | |
PCT/US1996/020744 WO1997024122A1 (en) | 1995-12-29 | 1996-12-20 | Vitronectin receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
NO983002D0 true NO983002D0 (en) | 1998-06-26 |
NO983002L NO983002L (en) | 1998-08-26 |
Family
ID=21738237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO983002A NO983002L (en) | 1995-12-29 | 1998-06-26 | Vitronectin receptor antagonists |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0895475A4 (en) |
JP (1) | JP2000502708A (en) |
KR (1) | KR19990076876A (en) |
CN (1) | CN1209060A (en) |
AU (1) | AU1353897A (en) |
BR (1) | BR9612378A (en) |
CA (1) | CA2241724A1 (en) |
CZ (1) | CZ203798A3 (en) |
HU (1) | HUP9901116A2 (en) |
IL (1) | IL125034A0 (en) |
MX (1) | MX9805253A (en) |
NO (1) | NO983002L (en) |
PL (1) | PL327919A1 (en) |
TR (1) | TR199801255T2 (en) |
WO (1) | WO1997024122A1 (en) |
ZA (1) | ZA9610855B (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996006087A1 (en) * | 1994-08-22 | 1996-02-29 | Smithkline Beecham Corporation | Bicyclic compounds |
CA2242877A1 (en) * | 1996-01-16 | 1997-07-24 | Merck & Co., Inc. | Integrin receptor antagonists |
ES2185009T3 (en) * | 1996-04-10 | 2003-04-16 | Merck & Co Inc | ALFA AND BETA 3 'ANTAGONISTS. |
US20030125317A1 (en) | 1996-10-02 | 2003-07-03 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
DE19653647A1 (en) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin receptor antagonists, their preparation and their use |
US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
DE19653645A1 (en) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin receptor antagonists, their preparation and their use |
US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
JP2002510328A (en) * | 1997-07-25 | 2002-04-02 | スミスクライン・ビーチャム・コーポレイション | Vitronectin receptor antagonist |
JP2002508323A (en) * | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | Integrin receptor antagonist |
UY25421A1 (en) * | 1998-03-10 | 2001-07-31 | Smithkline Beecham Corp | VITRONECTIN RECEPTOR ANTAGONISTS |
JP4778612B2 (en) * | 1998-04-01 | 2011-09-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | PDEIV-inhibiting pyridine derivatives |
GB9812088D0 (en) * | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
SE9803518D0 (en) * | 1998-10-15 | 1998-10-15 | Astra Pharma Prod | Novel compounds |
CA2358855A1 (en) | 1999-02-03 | 2000-08-10 | Merck & Co., Inc. | Benzazepine derivatives as alpha-v integrin receptor antagonists |
US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
BR0012683A (en) | 1999-07-21 | 2002-04-16 | American Home Prod | Selective bicyclic antagonists for the alpha-beta3 integrin |
EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
DE10028575A1 (en) | 2000-06-14 | 2002-03-14 | Basf Ag | integrin |
FR2800067B1 (en) | 1999-10-21 | 2004-12-17 | Rhodia Chimie Sa | INTERMEDIATES FOR THE MANUFACTURE OF A BENZOFURANE OR NITROGEN BENZOTHIOPHENE DERIVATIVE IN POSITION 5 AND THEIR USES |
FR2820743B1 (en) | 2001-02-09 | 2005-02-25 | Pf Medicament | SYNTHESIS METHOD AND INTERMEDIARIES FOR THE PREPARATION OF PYRIDIN-2-YL-METHYLAMINE DERIVATIVES |
ES2366775T3 (en) | 2001-04-24 | 2011-10-25 | Merck Patent Gmbh | POLYTHERAPY USING ANTIANGIOGEN AGENTS AND TNF (alpha). |
JP4800216B2 (en) * | 2003-10-24 | 2011-10-26 | エグゼリクシス, インコーポレイテッド | p70S6 kinase modulator and methods of use |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
WO2006041046A1 (en) * | 2004-10-13 | 2006-04-20 | Sankyo Company, Limited | Pyridine derivative |
US7262210B2 (en) | 2005-04-20 | 2007-08-28 | Janssen Pharmaceutica N.V. | Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls |
EP1973569B1 (en) | 2006-01-18 | 2013-05-22 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
AR060901A1 (en) * | 2006-05-12 | 2008-07-23 | Jerini Ag | HETEROCICLICAL COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE |
AU2008207095B2 (en) | 2007-01-18 | 2013-08-29 | Merck Patent Gmbh | Specific therapy and medicament using integrin ligands for treating cancer |
EP2730282A1 (en) | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
CN102459249A (en) | 2009-05-22 | 2012-05-16 | 埃克塞里艾克西斯公司 | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases |
AU2010252280A1 (en) | 2009-05-25 | 2012-01-19 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
CN102939278B (en) * | 2009-12-17 | 2014-11-26 | 巴斯夫欧洲公司 | Method for producing higher ethanolamines |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
BR112016027778A2 (en) | 2014-05-30 | 2017-08-15 | Pfizer | USES OF CARBONITRIL DERIVATIVES, THEIR COMBINATION AND THEIR PHARMACEUTICAL COMPOSITION |
WO2017216727A1 (en) | 2016-06-13 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as inhibitors of dnmt1 |
EP3589627A4 (en) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
MA47692A (en) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6) |
US20200071322A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibiting (alpha-v)(beta-6) integrin |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3627754A (en) * | 1970-05-13 | 1971-12-14 | Hoffmann La Roche | Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts |
WO1993000095A2 (en) * | 1991-06-28 | 1993-01-07 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
NZ314922A (en) * | 1992-12-21 | 1998-11-25 | Smithkline Beecham Corp | Benzodiazepinones; nitrogen containing heterocyclic intermediates and pharmaceutical compositions |
JPH10504807A (en) * | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | Vitronectin receptor antagonist |
TR199801254T2 (en) * | 1995-12-29 | 1998-10-21 | Smithkline Beecham Corporation | Vitronectin receptor antagonists. |
ZA9610853B (en) * | 1995-12-29 | 1998-04-06 | Smithkline Beecham Corp | Processes and intermediates for preparing pharmaceuticals. |
-
1996
- 1996-12-20 JP JP9524556A patent/JP2000502708A/en active Pending
- 1996-12-20 HU HU9901116A patent/HUP9901116A2/en unknown
- 1996-12-20 AU AU13538/97A patent/AU1353897A/en not_active Abandoned
- 1996-12-20 KR KR1019980705003A patent/KR19990076876A/en not_active Application Discontinuation
- 1996-12-20 EP EP96945085A patent/EP0895475A4/en not_active Withdrawn
- 1996-12-20 BR BR9612378A patent/BR9612378A/en unknown
- 1996-12-20 CZ CZ982037A patent/CZ203798A3/en unknown
- 1996-12-20 WO PCT/US1996/020744 patent/WO1997024122A1/en not_active Application Discontinuation
- 1996-12-20 IL IL12503496A patent/IL125034A0/en unknown
- 1996-12-20 TR TR1998/01255T patent/TR199801255T2/en unknown
- 1996-12-20 CA CA002241724A patent/CA2241724A1/en not_active Abandoned
- 1996-12-20 CN CN96180099A patent/CN1209060A/en active Pending
- 1996-12-20 PL PL96327919A patent/PL327919A1/en unknown
- 1996-12-23 ZA ZA9610855A patent/ZA9610855B/en unknown
-
1998
- 1998-06-26 NO NO983002A patent/NO983002L/en not_active Application Discontinuation
- 1998-06-26 MX MX9805253A patent/MX9805253A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CZ203798A3 (en) | 1998-12-16 |
WO1997024122A1 (en) | 1997-07-10 |
NO983002L (en) | 1998-08-26 |
MX9805253A (en) | 1998-10-31 |
IL125034A0 (en) | 1999-01-26 |
KR19990076876A (en) | 1999-10-25 |
EP0895475A4 (en) | 2000-08-23 |
JP2000502708A (en) | 2000-03-07 |
CA2241724A1 (en) | 1997-07-10 |
HUP9901116A2 (en) | 2000-03-28 |
PL327919A1 (en) | 1999-01-04 |
CN1209060A (en) | 1999-02-24 |
AU1353897A (en) | 1997-07-28 |
BR9612378A (en) | 1999-07-13 |
ZA9610855B (en) | 1997-11-24 |
EP0895475A1 (en) | 1999-02-10 |
TR199801255T2 (en) | 1998-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO983001D0 (en) | Vitronectin receptor antagonists | |
NO983003D0 (en) | Vitronectin receptor antagonists | |
NO983002D0 (en) | Vitronectin receptor antagonists | |
NO965608D0 (en) | Vitronectin receptor antagonists | |
ATE312089T1 (en) | VITRONECTIN RECEPTOR ANTAGONISTS | |
NO972016D0 (en) | Indolyl-Y receptor antagonists | |
NO983737L (en) | IL-8 receptor antagonists | |
NO993350D0 (en) | Vitronectin receptor antagonists | |
FI960953A0 (en) | endothelin receptor antagonists | |
DE69812096T2 (en) | NEUROPEPTID Y RECEPTOR ANTAGONISTS | |
ID16742A (en) | ENDOTELIN RECEPTOR ANTAGONISTS | |
DE59610900D1 (en) | Adhesion receptor antagonists | |
NO20001514D0 (en) | Vitronectin receptor antagonist | |
NO20001407D0 (en) | Vitronectin receptor antagonists | |
ID24726A (en) | TROMBIN RECEPTOR ANTAGONISTS | |
NO20001515D0 (en) | Vitronectin receptor antagonist | |
NO20004503L (en) | Vitronectin receptor antagonists | |
BR9507220A (en) | Endothelin receptor antagonists | |
DZ2322A1 (en) | Vitronectin receptor antagonists. | |
ATE341324T1 (en) | ENDOTHELIN RECEPTOR ANTAGONISTS | |
DE69616364D1 (en) | ENDOTHELINE RECEPTOR ANTAGONISTS | |
NO20010620D0 (en) | Vitronectin receptor antagonists | |
BR9603432A (en) | Endothelin receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |